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Abstract 
Background: Of late there have been accounts of therapeutic failure and chloroquine resistance in Plasmodium vivax 
malaria especially from Southeast Asian regions. The present study was conducted to assess the therapeutic efficacy 
of chloroquine–primaquine (CQ–PQ) combined regimen in a cohort of uncomplicated P. vivax mono-infection.
Methods: A tertiary care hospital-based prospective study was conducted among adult cohort with mono-infection 
P. vivax malaria as per the World Health Organization’s protocol of in vivo assessment of anti-malarial therapeutic effi-
cacy. Participants were treated with CQ 25 mg/kg body weight divided over 3 days and PQ 0.25 mg/kg body weight 
daily for 2 weeks.
Results: Of a total of 125 participants recruited, 122 (97.6%) completed day 28 follow up, three (2.4%) participants 
were lost to follow-up. Eight patients (6.4%) were ascertained to have mixed P. vivax and Plasmodium falciparum infec-
tion by nested polymerase chain reaction test. The majority of subjects (56.8%, 71/125) became aparasitaemic on 
day 2 followed by 35.2% (44/125) on day 3, and 8% (10/125) on day 7, and remained so thereafter. Overall only one 
therapeutic failure (0.8%, 1/125) occurred on day 3 due to persistence of fever and parasitaemia.
Conclusions: CQ–PQ combined regimen remains outstandingly effective for uncomplicated P. vivax malaria and 
should be retained as treatment of choice in the study region. One case of treatment failure indicates possible resist-
ance which warrants constant vigilance and periodic surveillance.
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Background
Plasmodium vivax accounts for more than 50% of total 
malaria burden in India [1]. Chloroquine (CQ) in a dose 
of 25  mg/kg body weight over 3  days remains the rec-
ommended first-line treatment for all uncomplicated P. 
vivax malaria in India [2]. Additionally, for radical cure, 
a primaquine (PQ) dose of 0.25  mg/kg body weight for 
14 days has been recommended in all non-gravid adult P. 
vivax cases with normal glucose-6-phosphate dehydro-
genase (G6PD) activity [2]. Therapeutic and prophylactic 
failures of CQ in P. vivax have been observed in 23 coun-
tries across the globe, including India [3]. However, true 
resistance to CQ in P. vivax has been confirmed in only 
ten countries across the globe, excluding India [3].
Therapeutic assessment remains the mainstay of moni-
toring the efficacies of anti-malarial regimens and is 
recommended to be undertaken once every 2  years [1]. 
Surveillance of CQ–PQ combined regimen in P. vivax 
remains valid and provides useful indices where regional 
health policy mandates such [4]. This study was under-
taken to determine the therapeutic efficacy of CQ–PQ 
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combined regimen in adult P. vivax mono-infection 
cohort as per WHO’s protocol [4].
Methods
Study design and patients
A prospective cohort study was conducted among micro-
scopically proven symptomatic mono-infection P. vivax 
patients aged ≥18  years attending Kasturba Hospital 
(KH), Manipal from September 2012 until October 2014. 
Patients were excluded if they had other febrile illnesses 
including mixed malaria or P. vivax malaria treated with 
artesunate combination therapy or prior anti-malarial 
medication outside KH before presentation or pregnancy 
or unwillingness to provide a written informed consent.
Ethics statement
Ethical approval (IEC 193/2011) was obtained from the 
institutional ethics committee of Kasturba Medical Col-
lege and Kasturba Hospital, Manipal University, Mani-
pal. Participation in study was strictly voluntary and each 
participant had privilege to retract their participation 
any time throughout the study. Patients’ information and 
study data were anonymized.
Sample size calculation
Presuming the proportion of anti-malarial treatment fail-
ure (ATF) of CQ–PQ combined regimen to be 5%, for a 
desired precision of 5% and confidence interval of 95%, a 
cohort of 73 microscopically proven P. vivax mono-infec-
tion cases were required [4]. Furthermore, to adjust for a 
20% expected loss to follow-up and 20% expected with-
drawal/protocol violation the final required sample size 
was determined as 122 subjects.
Blood sample collection and processing
The date of initiation of anti-malarial medication and 
study enrolment were the same and was considered as 
day 0. Peripheral blood smear was examined on days 0, 
2, 3, 7, 14, 21, and 28. Before initiation of anti-malarial 
medications, 1  ml venous blood sample was obtained 
from each participant in an ethylenediaminetetraacetic 
acid (EDTA) anticoagulated vacutainer and used for 
making peripheral smears, total leukocyte count and 
DNA extraction. On subsequent follow-up days capillary 
blood sample was obtained by finger prick on cleaned 
glass slides to prepare both thin and thick smears. Leish-
man’s stained thin and thick peripheral blood smears 
were examined to ascertain the P. vivax mono-infection 
and to estimate the parasite index (PI), respectively. DNA 
was extracted from 200 µL of EDTA anticoagulated blood 
using QIAamp DNA Blood Mini Kit as per the manufac-
turer’s instructions and stored at −20°C until conduct of 
nested polymerase chain reaction (nPCR) test for confir-
mation of the mono-infection with P. vivax malaria.
Variables
Independent variables
Axillary temperature was recorded on each respective 
follow-up day as mentioned above. Participants’ total 
leukocyte count per µL was estimated in constituent 
laboratory of KH, Manipal by Beckman Coulter® LH 750 
Haematology Analyzer and used for PI calculation. PI 
was determined as the absolute number of asexual and/
or sexual parasites present in 1  µL of peripheral blood, 
as described elsewhere [5]. Peripheral blood smears were 
examined under Olympus CH20i microscope and a mean 
PI by three consecutive calculates was derived for further 
analysis. Relevant demographic and clinical data of par-
ticipants were recorded using a customized proforma.
Dependent variable
ATF was considered as the primary outcome. Anti-
malarial therapeutic responses were classified as per 
WHO’s recommendation for P. vivax [4]. However, for in-
hospital patients ‘deteriorating clinical condition requir-
ing hospitalization with presence of parasitaemia’ was 
not considered as ATF, owing to the study setting being a 
tertiary care hospital and the patients being hospitalized 
as per the clinicians’ judgement before the diagnosis of 
malaria and initiation of anti-malarial treatments.
Confirmation of Plasmodium vivax mono‑infection by nPCR 
test
Small sub-unit ribosomal RNA was amplified using 
genus and species-specific oligonucleotide primers sepa-
rately for only P. vivax and P. falciparum, as described by 
Snounou et  al. [6], with modifications  in the amplifica-
tion conditions of the second reaction. All reactions were 
carried out in a final volume of 20 µL containing 2 mM 
MgCl2, 50 mM KCl, 10 mM Tris–HCl pH 8.3, 125 µM of 
each dNTPs, 250  nM of each oligonucleotide primers, 
0.5 units of Taq DNA polymerase (Sigma-Aldrich) and 
1 µL of template DNA. Product of the first amplification 
reaction was further amplified in second reaction as step 
1: 94°C for 5 min; step 2: 94°C for 30 s; step 3: 55°C for 
30 s; step 4: 72°C for 1 min; steps 2–4 for 10 cycles, then 
step 6: 94°C for 10  s; step 7: 60°C for 10  s; step 8: 72°C 
for 1  min; steps 6–8 for 20 cycles and then final exten-
sion at 72°C for 5  min followed by termination tem-
perature at 4°C. Reference samples of mono-infection P. 
vivax and P. falciparum were procured from the National 
Institute of Malaria Research (ICMR), Sector 8, Dwarka, 
Delhi-110077 (India). DNA extracted from the reference 
samples were used as positive controls in every batch of 
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nPCR tests. While, DNA extracted from a normal healthy 
volunteer was used as negative control.
Patients’ treatments
On presentation, patients were treated symptomatically 
as required. After confirmation of P. vivax malaria, spe-
cific anti-malarial medications were prescribed as per 
the clinicians’ judgements and the national guideline for 
treatment of malaria [2]. Resochin (chloroquine phos-
phate 250  mg) manufactured by Bayer Pharmaceuticals 
Private Limited Bayer House Central Avenue, Hiranan-
dani Estate, Thane—400607, Maharashtra, India and 
Malirid (primaquine phosphate 7.5 mg) manufactured by 
IPCA Laboratories Pvt. Ltd. 123-AB, Kandivli Industrial 
Estate, Kandivli (West)Mumbai 400 067, Maharashtra, 
India was administered to the study cohort. All patients 
were instructed to take primaquine after having food and 
not to take while empty stomach. PQ was administered 
only after estimation of G6PD activity, i.e., immediately 
after completion of CQ dosage. Activity of erythrocytes’ 
G6PD enzyme was quantified by manual spectropho-
tometric kinetic ‘gold standard’ method. The enzyme 
activity was determined by measurement of increase 
in reduced form of nicotinamide adenine dinucleo-
tide phosphate (NADPH) concentration, that strongly 
absorbs UV light (340 nm). Mild to moderate G6PD defi-
cient patients’ were treated with 0.75  mg/kg stat dose 
of PQ follow by weekly once same dose for subsequent 
7  weeks. Patients’ adherence to anti-malarial regimens 
was ascertained by direct observation for all inpatients 
during their hospital stay and for outpatients by passive 
reminder (group messages over mobile phones) and by 
documenting the emptied stripes of medicines on each 
follow-up day.
Statistical analyses
Gaussian distribution of continuous variables was deter-
mined by Kolmogorov–Smirnov test. Data having normal 
distribution were summarized as mean with standard 
deviation and compared by independent t test. Skewed 
data were summarized as median with interquartile range 
and compared by Mann–Whitney U test. Categorical 
variables were summarized as frequency with proportion 
and compared by either χ2 test or Fischer’s exact test. All 
tests of significance were two-tailed with a p value <0.05 
indicating statistical significance. Parasite index was sum-
marized as geometric mean with 95% confidence interval 
of geometric mean. The probability of therapeutic failure 
was assessed by life table analysis. Data analysis was done 
using Statistical Package for the Social Sciences version 
15.0 (SPSS, South Asia, Bangalore, India).
Results
Patients’ clinical‑demographic profile
A total of 125 participants sustaining the study selec-
tion criteria were enrolled. Pertinent clinical and demo-
graphic characteristics of the study cohort have been 
summarized in Table  1. Significantly (p  <  0.05) higher 
axillary temperature at presentation and longer deferves-
cence time was noted among hospitalized than ambula-
tory care participants. Mean duration of hospitalization 
of inpatients was 4.3 ± 1.5 days.
Table 1 Clinical-demographic profile of  study participants (N =  125) with  P. vivax monoinfection from  southwestern 
India treated with chloroquine (25 mg/kg over 3 days) followed by primaquine (0.25 mg/kg daily for 14 days)
a Geometric mean with 95% confidence interval of geometric mean.
$ p value obtained by either independent t test or Mann–Whitney U test or Chi square test as applicable, p values <0.05 are shown in italic face.
Settings Outpatient (N = 41) Inpatient (N = 84) p value$
Variables Mean ± SD/median (IQR) Range Mean ± SD/median (IQR) Range
Age in years 33.6 ± 13.2 18–76 35.3 ± 13.3 18–73 0.49
Duration of fever in days 3 (2, 4) 1–30 4 (3, 6) 1–60 0.14
Axillary temperature at presentation (oC) 99.2 ± 1.0 98.6–102 100.3 ± 1.7 98.6–104 <0.001
Defervescence time in hours 8 (0, 17) 0–48 12 (4.5, 33.5) 0–148 0.001
Parasite index on day ‘0’ (parasites/µL) 1,164 (803–1,686)a 41–11,640 1,255 (932–1,690)a 64–21,700 0.17
Settings Outpatient (N = 41) Inpatient (N = 84) p value$
Variables Frequency (%) Frequency (%)
Gender (males) 39 (95.1) 71 (84.5) 0.14
Empiric antibiotics 0 1 (1.2) 1.00
Treatment failure 0 1 (1.2) 1.00
nPCR proven mixed malaria 3 (7.3) 5 (6) 0.72
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Patients’ treatments
Chloroquine (25  mg/kg body weight over 3  days) and 
primaquine (0.25  mg/kg body weight daily for 2  weeks) 
standard anti-malarial regimen for P. vivax was given 
to all subjects except one participant whose G6PD was 
low (5.5 U/gm Hb), thus was given a 45 mg stat PQ dose 
followed by weekly dose of 45 mg PQ for next 7 weeks. 
Mean G6PD activity in study cohort was determined 
as 15.2 ± 4.1 U/gm Hb and ranged from 5.5 to 27.2 U/
gm Hb. A complete adherence for the prescribed CQ–
PQ regimens was noted among study cohort. Empiric 
antibiotic (ceftriaxone) was administered to one (1.2%) 
inpatient.
Study outcomes
A total of 122 (97.6%) participants completed day 28 fol-
low-up. Three participants (2.4%) were lost to follow up 
after day 3. One of them remained parasitaemic on day 
3 but had become afebrile within 24 h of hospitalization. 
Another two participants had become aparasitaemic by 
day 3 and their defervescence time was less than 24  h. 
More than half of the subjects (56.8%, 71/125) became 
aparasitaemic on day 2 followed by 35.2% (44/125) on day 
3; and 8% (10/125) on day 7 and remained so thereafter 
to day 28 (Fig. 1). Despite having history of fever within 
preceding 3 days, 24% (30/125) subjects were afebrile at 
presentation and remained so throughout study duration. 
Among febrile population, time to defervescence by day 
2 was noted in 95.8% (91/95), by day 3 in 97.9% and by 
day 7 all participants had become afebrile and remained 
so throughout the study (Fig.  1). Overall only one ATF 
(0.8%, 1/125) occurred on day 3 (persistence of fever and 
parasitaemia, 2,200 parasite/µL on day 0 to 9,652 para-
site/µL on day 2 to 7,012 parasite/µL on day 3). After this 
time point, attending physician changed the anti-malarial 
medication of that patient from CQ to artemether–lume-
fantrine (480–2,880  mg) combination and PQ standard 
regimen. Subsequently, on day 7 the patient was found 
to become aparasitaemic and afebrile. This one case 
of ATF was indeed an early treatment failure (ETF), 
whereas all other participants did have adequate clinical 
and parasitological response (ACPR) [4]. Due to only one 
valid survival function, i.e., therapeutic failure outcome, 
Kaplan–Meier plot could not be generated. The cumula-
tive incidence of therapeutic failure by day 28 was only 
1% (Table 2). No mortality occurred till 28 day follow up 
in the study cohort.
Nested PCR results
Nested PCR test confirmed a total of 116 (93.6%) partici-
pants to have P. vivax mono-infection. However, the test 
revealed mixed (P. vivax and P. falciparum) infections 
among total of eight (6.4%) subjects. The DNA sample of 
one participant (0.8%) could not be amplified. Notably, 
the one subject with therapeutic failure had PCR proven 
P. vivax mono-infection.
Discussion
Prime index of suspicion of emergence/existence of 
resistance to anti-malarial drugs surfaces during ther-
apeutic drug trials or surveillances. Present study was 
undertaken to determine the therapeutic efficacy of 
CQ–PQ combined regimen in P. vivax malaria. The KH, 
Manipal caters for over 200 malaria patients annually 
from southwestern India comprising Goa, coastal Kar-
nataka and Kerala. Notably, P. vivax infection consti-
tutes more than 55% of total annual malaria incidence 
in KH, Manipal. Male preponderance observed in the 
current study is a common finding and has also been 
reported from the same hospital [7–9]. Significantly, 
Fig. 1 Pattern of parasitaemia and fever clearance in cohort of P. vivax 
monoinfection patients from southwestern India treated with chlo-
roquine (25 mg/kg over 3 days) followed by primaquine (0.25 mg/kg 
daily for 14 days).
Table 2 Life table showing estimates of  risk of  therapeu-
tic failure during  28  days follow-up in  cohort of  P. vivax 
monoinfection patients from  southwestern India treated 
with  chloroquine (25  mg/kg over  3  days) followed by  pri-
maquine (0.25 mg/kg daily for 14 days)








0 125 0 0 1.00 0
2 125 0 0 1.00 0
3 125 0 1 0.99 0.01
7 124 3 0 0.99 0.01
14 121 0 0 0.99 0.01
21 121 0 0 0.99 0.01
28 121 0 0 0.99 0.01
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(p  <  0.05) high axillary temperature at presentation 
and longer time to defervescence among inpatients 
than outpatients is a reflection of more sick/febrile 
patients receiving in hospital care. Notably, about 99% 
therapeutic efficacy of CQ–PQ combined regimen as 
observed in the present study was reported previously 
from the same hospital during the years 2007–2009 
[10]. However, the previous study did lack the confir-
mation of P. vivax mono-infection by PCR test and also 
did not have rigorous 28 days follow-up, as in the cur-
rent study. Furthermore, similar therapeutic efficacy 
until day 28 has also been reported from other parts 
of India viz. 100% (41/41) from Mangalore [11], 98.1% 
(105/107) from Chennai [12] and 96.9% (63/65) from 
Gujarat [13] for CQ only and 100% (103/103) from 
Kolkata [14] for CQ–PQ combined regimen during 
the years 2003–2012. Notably, CQ–PQ combined regi-
men is known to have superior efficacy than CQ alone 
for preventing P. vivax recurrences [14–16]. Nonethe-
less, of the published literature from India, only a case 
report dating back over two decades confirms CQ fail-
ure in P. vivax despite having adequate plasma concen-
tration of CQ [17].
The hub of global CQ resistance in P. vivax is in Indo-
nesia [15, 18, 19]. Probable CQ-resistant P. vivax in India 
has been documented from north, northeast and western 
parts, whereas CQ remains sensitive throughout south-
ern India [15]. Importantly, surging CQ resistance in P. 
vivax across eastern neighbouring countries of India, 
including Myanmar [20], Thailand [21] and Vietnam [22] 
is a matter of concern and this urges an immediate imple-
mentation of effective preventive measures to check the 
invasion of any resistant P. vivax strain from those coun-
tries along with travellers and/or migrants.
Strengths and limitations
The present study poses considerable strength over 
studies which did not have PCR-proven mono-infec-
tion P. vivax cases. Statistically, valid sample size, 
robust analysis and standard methodology render the 
study outcomes legitimately comparable with parallel 
series across the globe. Outstanding therapeutic effi-
cacy of CQ–PQ combined regimen for P. vivax malaria 
observed in the current study is augmenting evidence 
to support the continuation of the existing national 
anti-malarial drug policy for P. vivax malaria in India. 
The probably resistant case of one therapeutic fail-
ure could not be ascertained as truly resistant P. vivax 
strain. Arguably, persistence of fever and increasing 
parasitaemia from 2,200 parasite/µL on day 0 to 9,652 
parasite/µL on day 2 and residual 7,012 parasite/µL on 
day 3 despite completion of CQ dosage features a true 
resistant P. vivax strain. However, this argument could 
possibly have been true only if CQ and desethylchloro-
quine concentration in participant’s blood [16, 23] was 
estimated on the day of therapeutic failure and/or anal-
ysis of molecular markers for CQ resistance [14, 24, 25] 
was done.
The nPCR test proved an insubstantial proportion of 
participants to have mixed malaria infection. However 
those entities of mixed malaria seemed inconsequential 
clinically as nPCR proven mixed malaria did not affect 
either the nature of illness or treatment/outcome and 
conclusions of the study. Notably, this inference of clini-
cal inconsequentiality of merely nPCR-proven mixed 
malaria must be methodically evaluated further as it is 
beyond the scope of the current study. Lost to follow-up 
ensued in only three patients but seemingly they all had 
ACPR until their day 3 follow-up. However, we cannot 
rule out the possibility of treatment failure beyond day 3. 
Remarkably, this study did not assess the efficacy of CQ 
alone as per the WHO protocol [4], rather a permitted 
deviation from it i.e., assessment of CQ–PQ combined 
regimen as it was suitable in the respective study setting. 
Therefore, the findings of this study can only be applica-
ble to population exempting any contraindications for 
PQ administration. Similar studies in future should with-
hold PQ administration till day 28 as recommended pri-
marily by the WHO [4].
Conclusions
Therapeutic efficacy of CQ–PQ combined regimen in 
uncomplicated P. vivax malaria remains intact in the 
study region and thus must be continued as the treat-
ment of choice for uncomplicated P. vivax malaria. Peri-
odic surveillances must be conducted to remain vigilant 
for taking immediate measures to prevent the emergence 
and spread of anti-malarial resistance in P. vivax.
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